Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label first-line FOLFOX6m plus panitumumab biomarker study in KRAS wild-type metastatic colorectal cancer
2009-017331-18Phase 2Completed
- Sponsor
- GEMCAD
- Start
- Mar 2010
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab, oxaliplatin, fluorouracil and folinic acid in metastatic colorectal adenocarcinoma (mCRC), sponsored by GEMCAD. Primary endpoint: Progression-free survival. Started Mar 2010; status: completed.
02
Drugs
panitumumaboxaliplatinfluorouracilfolinic acid
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-017331-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017331-18.